冷冻保存全血的微核检测
2024年2月23日
5.1K 次观看
在这里，我们提出了一种优化的方案，用于对冷冻保存的全血样品进行胞质分裂阻滞微核测定。这种用于微核分析的全血冷冻保存优化方法是大规模取样和多中心研究的可靠技术，也可用于其他血液相关检测。
我们的研究主要集中在检查电离辐射对健康组织的影响。我们正在研究癌症患者和DNA修复障碍患者的染色体放射敏感性。此外，我们还参与了生物不对称性研究，评估了暴露于电离辐射引起的DNA损伤。
为了推进我们领域的研究，我们使用自动化显微系统进行高通量分析。新鲜全血样本是微核测定的首选样本类型，因为它很容易获得，对患者的不适感最小。然而，在时间限制下，立即处理的需要可能在物流上具有挑战性。
全血样品的冷冻允许重复分析，而无需进一步进行额外取样。该程序是在大规模和多中心研究中储存血液样本的一种简单且省时的方法。全血冷冻保存方案不仅为微核测定提供了优势，而且为其他需要淋巴细胞增殖的细胞遗传学测定或功能测定提供了优势。
概述
本文介绍了一种优化的细胞质分裂阻断微核测定法，使用冷冻保存的全血样本。该方法提高了大规模和多中心研究的可靠性，适用于各种血液相关测定。
关键研究组成部分
科学领域
- 神经科学
- 细胞遗传学
- 放射生物学
背景
- 研究聚焦于电离辐射对健康组织的影响。
- 研究癌症患者和DNA修复紊乱患者的染色体辐射敏感性。
- 调查电离辐射暴露造成的DNA损伤。
- 利用自动化系统进行高通量分析。
研究目的
- 开发可靠的血样冷冻保存方法。
- 促进无需额外采样的重复分析。
- 提高微核测定和其他细胞遗传学测定的效率。
使用的方法
- 解冻和处理冷冻血样。
- 血细胞的离心和重新悬浮。
- 细胞的培养和辐射以刺激分裂。
- 显微镜检查和微核计数。
主要结果
- 从冷冻保存的样本中成功回收活细胞。
- 微核产量随辐射剂量呈线性二次增加。
- 在对照样本中观察到背景微核产量。
结论
- 优化的协议适用于大规模研究。
- 为微核和其他测定提供了可靠的方法。
- 提高了对辐射暴露引起的DNA损伤的理解。
常见问题
什么是细胞质分裂阻断微核测定法？
它是一种通过计数细胞中的微核来评估DNA损伤的方法。
为什么冷冻保存对血样重要？
它允许进行重复分析而无需额外采样，使研究更加高效。
电离辐射如何影响健康组织？
电离辐射可以诱导DNA损伤，研究其对染色体稳定性的影响。
在这项研究中使用自动化系统的优点是什么？
自动化系统能够实现高通量分析，提高数据收集的效率和准确性。
研究结果的意义是什么？
研究结果提供了对DNA损伤机制的见解，并改进了细胞遗传学测定的方法。
Executive Industry Relevance
The cytokinesis-block micronucleus (CBMN) assay on cryopreserved whole blood enables scalable, reproducible genotoxicity and radiosensitivity testing critical for early-stage drug discovery and translational research. By decoupling sample collection from immediate processing, this protocol supports large-scale, multi-center studies and enhances portfolio-wide assay standardization. The approach directly addresses logistical barriers in biopharma R&D, facilitating robust mechanistic de-risking and predictive confidence in DNA damage assessment workflows.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables systematic interrogation of DNA damage response pathways in disease-relevant human samples.
- Supports functional target validation by quantifying chromosomal radiosensitivity and genotoxic effects.
- Facilitates mechanistic de-risking for candidate targets involved in DNA repair and cell cycle regulation.
- Improves predictive confidence for portfolio triage in radiobiology and oncology programs.
Screening & Assay Development
- Provides validated, reproducible biological systems for downstream genotoxicity and cytogenetic assays.
- Standardizes assay conditions across sites and time points, supporting high-throughput screening readiness.
- Enables quantitative measurement of micronuclei as a robust readout for compound evaluation.
- Supports scalability and platform reuse in multi-center and longitudinal studies.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by enabling DNA damage quantification in clinically relevant samples.
- Ensures continuity from discovery through preclinical validation for radiosensitivity and genotoxicity endpoints.
- Reduces biological risk in advancing candidates targeting DNA repair or cell cycle pathways.
- Provides mechanistic insight for risk-adjusted advancement decisions in oncology and radiobiology pipelines.
Pipeline & Workflow Integration
This protocol integrates from early discovery through lead identification and preclinical validation, supporting hypothesis-driven research and standardized analytics in DNA damage assessment.
- Discovery Biology: Enables robust hypothesis testing and pathway clarification for DNA damage and repair mechanisms.
- Screening: Delivers reproducible, quantitative micronucleus readouts for assay development and compound screening.
- Analytics: Provides statistical outputs for comparing genotoxic effects across conditions and time points.
- Translational Research: Supports biomarker alignment and preclinical continuity in radiobiology and oncology studies.
- Enterprise Reuse: Establishes a reusable, standardized capability for cytogenetic and functional assays requiring proliferating lymphocytes.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in DNA damage assessment.
- Operational Value: Enhances standardization, reproducibility, and scalability for multi-site studies.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling robust, repeatable analyses.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of candidates in genotoxicity-sensitive programs.
Implementation Considerations
- Requires expertise in cytogenetics, cell culture, and fluorescence microscopy.
- Needs access to cryopreservation infrastructure and automated microscopy systems for high-throughput analysis.
- Demands cross-team standardization of sample handling and assay protocols for reproducibility.
- Adaptable to various cytogenetic and functional assays involving proliferating lymphocytes.
- Dependent on validated protocols for consistent sample thawing, processing, and quantitative analysis.
Biopharma FAQs
Why does null hypothesis testing matter for micronucleus quantification?
Null hypothesis testing in micronucleus quantification enables objective assessment of DNA damage differences between irradiated and control samples, supporting robust target validation and mechanistic de-risking in discovery workflows.
How does independent variable isolation fit the cryopreserved blood assay pipeline?
Isolating variables such as radiation dose and sample handling ensures that observed micronucleus yields reflect true biological effects, enhancing predictive confidence and assay reliability across multi-center studies.
What do quantitative dependent variable measurements enable in CBMN assays?
Quantitative measurement of micronuclei provides reproducible endpoints for comparing genotoxicity, facilitating compound screening, dose-response analysis, and cross-study standardization in biopharma R&D.
Why are replication requirements critical for cross-functional collaboration?
Replication of the CBMN assay using cryopreserved samples allows multiple teams to validate findings, ensuring data robustness and enabling coordinated decision-making across discovery and translational research groups.
What statistical analysis capabilities are required before CBMN assay implementation?
Robust statistical analysis is needed to interpret micronucleus frequency data, establish dose-response relationships, and support go/no-go decisions, ensuring the assay's value in portfolio risk management and mechanistic studies.
